STOCK TITAN

Barinthus Biotherapeutics plc American (BRNS) Free Cash Flow by Year

BRNS

Barinthus Biotherapeutics plc American recorded an outflow of $48.0M in free cash flow in fiscal year 2025. This represents a decrease of 61.0% from the prior fiscal year. Over the trailing 12 months, Q3 FY2025 through Q2 FY2026, the same line adds up to an outflow of $26.4M in free cash flow. The table below carries 6 fiscal years, from 2020 to 2025, and the quarters Barinthus Biotherapeutics plc American has filed alongside them.

FY2025 annual
Free Cash Flow -$48.0M
YoY -61.0%
Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

BRNS Free Cash Flow by Fiscal Year

Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricTTMFY2510-KFY2410-KFY2310-KFY2210-KFY2110-KFY2010-K
Free Cash Flow-$26.4M-$48.0M-61.0%-$29.8M+47.0%-$56.3M-173.9%-$20.6M+39.0%-$33.7M-197.9%-$11.3M

TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.

BRNS Free Cash Flow by Quarter

Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-QQ1'2410-QQ4'2310-KQ3'2310-Q
Free Cash Flow-$8.1M+55.4%-$3.4M+77.4%-$4.2M-133.1%-$10.7M+41.4%-$18.1M-48.7%-$14.9M-22.9%$12.8M+164.8%-$18.3M-63.1%-$12.2M+38.9%-$12.1M-113.5%-$19.8M-65.6%-$11.2M-218.5%

What free cash flow means

Free cash flow is the cash operations produced over the period, less what the company spent on property, plant and equipment, so it answers what was left over rather than what was earned on paper.

More Barinthus Biotherapeutics plc American financials

Frequently Asked Questions

What was Barinthus Biotherapeutics plc American's free cash flow in fiscal year 2025?

Barinthus Biotherapeutics plc American recorded an outflow of $48.0M in free cash flow in fiscal year 2025.

How fast is Barinthus Biotherapeutics plc American's free cash flow growing?

Barinthus Biotherapeutics plc American (BRNS) free cash flow fell by 61.0% year over year, from -$29.8M to -$48.0M in fiscal year 2025.

What is Barinthus Biotherapeutics plc American's free cash flow over the last twelve months?

Barinthus Biotherapeutics plc American (BRNS) reported an outflow of $26.4M in free cash flow over the trailing 12 months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.

Across the 6 fiscal years this page covers, Barinthus Biotherapeutics plc American (BRNS) free cash flow went from -$11.3M in fiscal year 2020 to -$48.0M in fiscal year 2025.

Barinthus Biotherapeutics plc American (BRNS) reported -$8.1M in free cash flow in Q2 2026. This represents an increase of 55.4% from the same quarter a year earlier.

Free cash flow is the cash operations produced over the period, less what the company spent on property, plant and equipment, so it answers what was left over rather than what was earned on paper. This page lists what Barinthus Biotherapeutics plc American (BRNS) reported on that line in every period on record.